Literature DB >> 30628103

Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid.

Masahiro Kamata1,2, Yoshihide Asano2, Rino Shida2, Narumi Maeda2, Ayumi Yoshizaki2, Tomomitsu Miyagaki2, Tomohiko Kawashima3, Yayoi Tada1, Shinichi Sato2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30628103     DOI： 10.1111/1346-8138.14760

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  4 in total

Review 1.  Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Am J Clin Dermatol       Date:  2022-08-14       Impact factor: 6.233

2.  Bullous Pemphigoid Associated with Erythrodermic Psoriasis: A Case Report.

Authors:  Wenjuan Chen; Chen Peng; Jianfeng Zheng; Xiya Lu; Yangfeng Ding; Lina Su
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-07

Review 3.  Learning From Success and Failure: Biologics for Non-approved Skin Diseases.

Authors:  Reinhart Speeckaert; Jo Lambert; Nanja van Geel
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

Review 4.  Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.

Authors:  Masutaka Furue; Akiko Hashimoto-Hachiya; Gaku Tsuji
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.